MedTrace Logo

The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19

NCT05855395 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5815

Last updated 2023-07-12

No results posted yet for this study

Summary

This study is aimed to explore the dual-dimensional early intervention strategy of standard of care combined with host immunomodulation in elderly patients with mild and moderate COVID-19.

Conditions

Interventions

DRUG

Glucocorticoid

standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • WenHong Zhang, M.D. · Huashan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-26
Primary Completion
2024-05-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05855395 on ClinicalTrials.gov